MS 553

Drug Profile

MS 553

Latest Information Update: 22 Mar 2016

Price : $50

At a glance

  • Originator Pfizer
  • Developer Jiangsu MingSight-Relin Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Diabetic retinopathy

Most Recent Events

  • 01 Apr 2015 Phase-I clinical trials in Diabetic retinopathy (In volunteers) in Australia (PO) (NCT02406989)
  • 25 Mar 2015 Jiangsu MingSight Pharmaceuticals plans a phase I trial in Healthy volunteers in Australia (NCT02406989)
  • 06 Jul 2011 Preclinical trials in Diabetic retinopathy in China (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top